Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: final week 96 efficacy and safety results from a phase 2 study
Recommended Citation
Heo J, Fournier C, Ahn SH, Tsang TY, Coffin CS, Huang Y, Reggiani GM, Hui AJ, Elkhashab M, Chen C, Jafri S, Tan S, Zhao Y, Suri V, Flaherty JF, Gaggar A, Brainard D, Chuang W, Agarwal K, Gane E, Lim Y. Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: final week 96 efficacy and safety results from a phase 2 study. J Hepatol 2021; 75(2):S294.
Document Type
Conference Proceeding
Publication Date
7-1-2021
Publication Title
J Hepatol
Abstract
Background and aims: We have previously shown in renally impaired (RI) chronic hepatitis B (CHB) patients, including those with end-stage renal disease (ESRD) on hemodialysis (HD), that switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) and or other oral antivirals (OAVs) maintains high rates of viral suppression with stable bone and renal safety parameters at Week 48. Here we present the final Week 96 results. Method: In this Phase 2 study (NCT03180619), virally suppressed CHB patients (HBV DNA
Volume
75
Issue
2
First Page
S294
